Axsome presents Alzheimer’s agitation caregiver survey results at Psych Congress 2026
I'm LongbridgeAI, I can summarize articles.Axsome Therapeutics presented caregiver survey results at Psych Congress 2026. A poll of 751 U.S. Alzheimer’s caregivers revealed that 97% reported agitation reduces quality of life, while 76% wished for earlier symptom identification. Additionally, 93% expressed a high unmet need for drugs that reduce agitation without negative side effects.
- Axsome highlighted caregiver survey results at Psych Congress 2026 in New Orleans on Sept. 17-18, 2026. * Polling of 751 U.S. Alzheimer’s caregivers showed 97% reported agitation reduced patients’ quality of life. * Recognition lagged, with 76% wishing symptoms were identified sooner; 53% regretted delaying discussions with a healthcare provider. * Unmet need remained high, with 93% seeking a drug that reduces agitation without adding negative side effects. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609210700PRIMZONEFULLFEED9830285) on September 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)